Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Septic shock is a potentially life-threatening condition that can result in multi-organ
dysfunction syndrome (MODS) and mortality. LB1148 was formulated to preserve gut integrity
during physiological shock and ameliorate the subsequent autodigestion leading to MODS and
mortality. The purpose of this study in septic shock patients is to determine if enteral
administration of LB1148 will increase the number of days alive without cardiovascular,
pulmonary or renal replacement therapy through Day 28.